Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab vs Adalimumab in Biologic-Naive Psoriatic Arthritis
NCT03151551Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 4, randomised, open-label trial of ixekizumab in psoriatic arthritis (PsA) and plaque psoriasis, sponsored by Eli Lilly and Company. Primary endpoint: Simultaneous Achievement of American College of Rheumatology 50 and Psoriasis Area and Severity Index 100 at 24 weeks. Started Aug 2017; status: completed.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on NCT03151551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151551.